Masharani Umesh, Gjerde Christine, Evans Joseph L, Youngren Jack F, Goldfine Ira D
Department of Medicine, University of California, San Francisco, Diabetes Center, San Francisco, California 94143 , USA.
J Diabetes Sci Technol. 2010 Mar 1;4(2):359-64. doi: 10.1177/193229681000400218.
The purpose of this study was to determine whether a preparation of controlled-release alpha lipoic acid (CRLA) influences features of the polycystic ovary syndrome (PCOS).
We administered CRLA 600 mg twice daily for 16 weeks to six lean, nondiabetic patients with PCOS. Insulin sensitivity was measured by the euglycemic, hyperinsulinemic clamp. Plasma lipids were measured by vertical ultracentrifugation. Oxidative stress markers were measured in serum.
At the end of 16 weeks of CRLA treatment, there was a 13.5% improvement in insulin sensitivity as determined by the euglycemic, hyperinsulinemic clamp (p < .03). There was also a lowering of triglyceride levels (p < .04) and a shift in the distribution of low-density lipoprotein (LDL) particles toward the larger, more buoyant LDL subclass fraction. Two of the subjects who were not on oral contraception had an increased number of menstrual cycles. Controlled-release alpha lipoic acid treatment, however, was neither associated with an increase in plasma antioxidant capacity nor with a reduction in plasma lipid oxidation products.
These data suggest that the CRLA has positive effects on the PCOS phenotype. The effects of CRLA, however, may have been exerted through a mechanism not involving changes in oxidative stress.
本研究旨在确定控释α硫辛酸（CRLA）制剂是否会影响多囊卵巢综合征（PCOS）的特征。
我们对6名体型偏瘦、非糖尿病的PCOS患者每日两次给予600 mg CRLA，持续16周。通过正常血糖、高胰岛素钳夹试验测量胰岛素敏感性。通过垂直超速离心法测量血浆脂质。在血清中测量氧化应激标志物。
在CRLA治疗16周结束时，通过正常血糖、高胰岛素钳夹试验测定，胰岛素敏感性提高了13.5%（p < 0.03）。甘油三酯水平也有所降低（p < 0.04），低密度脂蛋白（LDL）颗粒的分布向更大、更具浮力的LDL亚类部分转变。两名未服用口服避孕药的受试者月经周期增多。然而，控释α硫辛酸治疗既未导致血浆抗氧化能力增加，也未使血浆脂质氧化产物减少。
这些数据表明CRLA对PCOS表型有积极影响。然而，CRLA的作用可能是通过一种不涉及氧化应激变化的机制发挥的。
